Novo Nordisk announced a strategic partnership with OpenAI to embed AI across drug discovery, manufacturing, supply chain, and commercial operations.
The collaboration aims to analyze complex datasets, accelerate candidate identification, and cut research‑to‑patient timelines, with full integration targeted by end‑2026.
Novo Nordisk shares rose about 2% in early trade, and the partnership includes data protection, governance, and human oversight measures.
OpenAI will upskill Novo’s global workforce, while CEOs Mike Doustdar and Sam Altman highlighted AI’s potential to transform healthcare.